首页> 外文期刊>JAMA: the Journal of the American Medical Association >Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis.
【24h】

Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis.

机译:LRP5和LRP6变异与骨质疏松症之间关联的大规模分析。

获取原文
获取原文并翻译 | 示例
           

摘要

CONTEXT: Mutations in the low-density lipoprotein receptor-related protein 5 (LRP5) gene cause rare syndromes characterized by altered bone mineral density (BMD). More common LRP5 variants may affect osteoporosis risk in the general population. OBJECTIVE: To generate large-scale evidence on whether 2 common variants of LRP5 (Val667Met, Ala1330Val) and 1 variant of LRP6 (Ile1062Val) are associated with BMD and fracture risk. DESIGN AND SETTING: Prospective, multicenter, collaborative study of individual-level data on 37,534 individuals from 18 participating teams in Europe and North America. Data were collected between September 2004 and January 2007; analysis of the collected data was performed between February and May 2007. Bone mineral density was assessed by dual-energy x-ray absorptiometry. Fractures were identified via questionnaire, medical records, or radiographic documentation; incident fracture data were available for some cohorts, ascertained via routine surveillance methods, including radiographic examination for vertebral fractures. MAIN OUTCOME MEASURES: Bone mineral density of the lumbar spine and femoral neck; prevalence of all fractures and vertebral fractures. RESULTS: The Met667 allele of LRP5 was associated with reduced lumbar spine BMD (n = 25,052 [number of participants with available data]; 20-mg/cm2 lower BMD per Met667 allele copy; P = 3.3 x 10(-8)), as was the Val1330 allele (n = 24,812; 14-mg/cm2 lower BMD per Val1330 copy; P = 2.6 x 10(-9)). Similar effects were observed for femoral neck BMD, with a decrease of 11 mg/cm2 (P = 3.8 x 10(-5)) and 8 mg/cm2 (P = 5.0 x 10(-6)) for the Met667 and Val1330 alleles, respectively (n = 25 193). Findings were consistent across studies for both LRP5 alleles. Both alleles were associated with vertebral fractures (odds ratio [OR], 1.26; 95% confidence interval [CI], 1.08-1.47 for Met667 [2001 fractures among 20 488 individuals] and OR, 1.12; 95% CI, 1.01-1.24 for Val1330 [1988 fractures among 20,096 individuals]). Risk of all fractures wasalso increased with Met667 (OR, 1.14; 95% CI, 1.05-1.24 per allele [7876 fractures among 31,435 individuals)]) and Val1330 (OR, 1.06; 95% CI, 1.01-1.12 per allele [7802 fractures among 31 199 individuals]). Effects were similar when adjustments were made for age, weight, height, menopausal status, and use of hormone therapy. Fracture risks were partly attenuated by adjustment for BMD. Haplotype analysis indicated that Met667 and Val1330 variants both independently affected BMD. The LRP6 Ile1062Val polymorphism was not associated with any osteoporosis phenotype. All aforementioned associations except that between Val1330 and all fractures and vertebral fractures remained significant after multiple-comparison adjustments. CONCLUSIONS: Common LRP5 variants are consistently associated with BMD and fracture risk across different white populations. The magnitude of the effect is modest. LRP5 may be the first gene to reach a genome-wide significance level (a conservative level of significance [herein, unadjusted P <10(-7)] that accounts for the many possible comparisons in the human genome) for a phenotype related to osteoporosis.
机译:背景:低密度脂蛋白受体相关蛋白5(LRP5)基因的突变会导致罕见的综合征,其特征是骨矿物质密度(BMD)改变。更常见的LRP5变异可能会影响普通人群的骨质疏松症风险。目的:为大规模证据证明LRP5的2个常见变异(Val667Met,Ala1330Val)和LRP6的1个变异(Ile1062Val)是否与骨密度和骨折风险相关。设计与设置:对来自欧洲和北美18个参赛团队的37,534个人的个人数据进行前瞻性,多中心,协作研究。在2004年9月至2007年1月之间收集了数据;在2007年2月至2007年5月之间对收集的数据进行了分析。通过双能X射线吸收法评估骨矿物质密度。通过问卷调查,医疗记录或射线照相文档来识别骨折;可通过常规监测方法(包括对椎骨骨折进行射线照相检查)确定的某些队列的事件骨折数据。主要观察指标:腰椎和股骨颈骨密度。所有骨折和椎骨骨折的患病率。结果:LRP5的Met667等位基因与腰椎BMD降低有关(n = 25,052 [有可用数据的参与者数量];每份Met667等位基因拷贝BMD降低20-mg / cm2; P = 3.3 x 10(-8)),和Val1330等位基因一样(n = 24,812;每份Val1330拷贝的BMD降低14-mg / cm2; P = 2.6 x 10(-9))。对于Met667和Val1330等位基因,股骨颈BMD观察到相似的效果,分别降低11 mg / cm2(P = 3.8 x 10(-5))和8 mg / cm2(P = 5.0 x 10(-6)) ,分别为(n = 25193)。两项LRP5等位基因的研究结果均一致。这两个等位基因均与椎体骨折有关(Met667 [20 488位个体中2001年骨折]的几率[OR]为1.26; 95%置信区间[CI]为1.08-1.47),OR为1.12; 95%CI为1.01-1.24。 Val1330 [1988年骨折,共有20,096个人]。 Met667(OR,1.14; 95%CI,每个等位基因[31,435位个体中的7876骨折]]和Val1330(OR,1.06; 95%CI,每个等位基因[7802骨折],也增加了所有骨折的风险31 199个人中])。调整年龄,体重,身高,绝经状态和激素治疗后,效果相似。通过调整骨密度可以部分地降低骨折风险。单倍型分析表明,Met667和Val1330变体均独立影响BMD。 LRP6 Ile1062Val多态性与任何骨质疏松症表型无关。经过多次比较调整后,除Val1330与所有骨折和椎骨骨折之间的所有关联外,其余所有关联仍然很明显。结论:常见的LRP5变异与BMD和不同白人人群的骨折风险始终相关。影响的程度适中。 LRP5可能是第一个达到与骨质疏松症相关的表型的基因组范围的显着性水平基因(保守水平的显着性水平[此处为未经调整的P <10(-7),这说明了人类基因组中的许多可能比较)) 。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号